drugset / Trial / NCT01018368

Study of VX-770 and Rifampin in Healthy Male Subjects

NCT01018368

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedCrossoverOpen-labelTreatment

Summary

The objectives of this study are to evaluate the effects of multiple doses of rifampin on the single-dose pharmacokinetics of VX 770.

Timeline

Start
2009-11
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivacaftor Other / unclassified 150 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications